EMD 1.89% 5.2¢ emyria limited

one liner about RX5 is not really reassuring. they haven't told...

  1. fup
    1,105 Posts.
    lightbulb Created with Sketch. 97
    one liner about RX5 is not really reassuring. they haven't told the market that it needs (and apparently is already undergoing?) ethics re-approval is a dog move by the company given how long ethics approvals take. RX5 is the company's only drug with a commercial partnership and they are stuck in a p3 trial that is going to be at least 1year overdue. clinical revenues of $1m/qtr isn't going to cover operating costs.
 
watchlist Created with Sketch. Add EMD (ASX) to my watchlist
(20min delay)
Last
5.2¢
Change
-0.001(1.89%)
Mkt cap ! $21.26M
Open High Low Value Volume
5.3¢ 5.5¢ 5.1¢ $25.69K 480.4K

Buyers (Bids)

No. Vol. Price($)
1 15000 5.3¢
 

Sellers (Offers)

Price($) Vol. No.
5.7¢ 50000 1
View Market Depth
Last trade - 15.36pm 03/07/2024 (20 minute delay) ?
EMD (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.